Recent Updates
Recently added Catalysts

terbutaline 'as needed'+ placebo budesonide

Phase 3

Asthma | Small molecule | Respiratory |AstraZeneca PLC|Last Updated: Nov 15, 2019

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment3,850

FDA Designations

No designations recorded

Clinical trial landscape

terbutaline 'as needed'+ placebo budesonide · 1 trial · 1 indication

Phase 3 1
NCT02149199A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.Asthma
COMPLETED3,850 Analytics
PHASE3COMPLETED
A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.
AsthmaUnlock trial analytics

Study Endpoints

Primary Endpoints

'Well-controlled Asthma Week' - a Derived Binary Variable (Yes/No)
Weekly, up to 52 weeks

A well-controlled asthma week is defined as the fulfilment of both conditions A) and B) below: A) Two or more of the following criteria are fulfilled: - No more than 2 days with a daily asthma symptom score \>1 - No more than 2 days of 'as needed' medication use, up to a maximum of 4 occasions per week (multiple occasions per day should be regarded as separate occasions) - Morning PEF ≥80% of Predicted Normal every day B) Both of the following criteria are fulfilled: - No nighttime awakenings due to asthma - No additional inhaled and/or systemic glucocorticosteroid treatment due to asthma. The binary variable well-controlled asthma week was derived for each patient and study week. In addition, for each week, the percent of patients with well-controlled asthma week was derived. It is required that the eDiary had to be completed on at least 5 days in a week to be a well-controlled asthma week.

Secondary Endpoints

Number of Participants Experiencing at Least One Severe Asthma Exacerbation
Day 1 up to 52 weeks
Number of Participants Experiencing at Least One Moderate or Severe Asthma Exacerbation
Day 1 up to 52 weeks
Average Change From Baseline in Pre-dose Forced Expiratory Volume in 1 Second (FEV1)
Study weeks 0,4,16,28,40,52
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Symbicort "as needed"+placebo Pulmicort bidEXPERIMENTALSymbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' + Placebo Pulmicort Turbuhaler 200 μg bid
terbutaline "as needed"+placebo Pulmicort bidACTIVE_COMPARATORterbutaline Turbuhaler 0.4 mg 'as needed' + placebo Pulmicort 200 μg Turbuhaler bid
Pulmicort bid + terbutaline "as needed"ACTIVE_COMPARATORPulmicort 200 μg Turbuhaler bid + terbutaline 0.4 mg Turbuhaler 'as needed'

Interventions

NameTypeDescription
budesonide/formoterol 'as needed' + budesonide placebo bidDRUGSymbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
terbutaline 'as needed' + placebo budesonide bidDRUGTerbutaline 0.4 mg powder for inhalation 'as needed' plus placebo Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
budesonide bid + terbutaline 'as needed'DRUGPulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
Unlock Study Design Details

Eligibility Criteria

Age Range12 Years to 130 Years
SexALL
Healthy VolunteersNo
Study Sites255

INCLUSION CRITERIA 1. Provision of informed consent prior to any study specific procedures. For patients under-age, signed informed consent from both the patient and the patient's parent/legal guardian is required 2. Male or Female, ≥12 years of age 3. Documented diagnosis of asthma for at least 6 m...

Countries:AustraliaBrazilBulgariaCanadaChileChinaHungaryMexicoPeruPhilippinesPolandRomaniaRussiaSouth AfricaSouth KoreaUkraineUnited KingdomVietnam
Unlock Eligibility Criteria